Congestive Heart Failure
SPORANOX® (itraconazole) Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of SPORANOX® Capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions and ADVERSE REACTIONS: Post-marketing Experience for more information.)
Drug Interactions: Coadministration of cisapride, pimozide, quinidine, dofetilide, or levacetylmethadol (levomethadyl) with SPORANOX® (itraconazole) Capsules, Injection or Oral Solution is contraindicated SPORANOX®, a potent cytochrome P450 3A4 isoenzyme system (CYP3A4) inhibitor, may increase plasma concentrations of drugs metabolized by this pathway. Serious cardiovascular events, including QT prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and/or sudden death have occurred in patients using cisapride, pimozide, levacetylmethadol (levomethadyl), or quinidine, concomitantly with SPORANOX® and/or other CYP3A4 inhibitors. See CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactions for more information.
SPORANOX® is the brand name for itraconazole, a synthetic triazole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers.
SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in
immunocompromised and non-immunocompromised
Blastomycosis, pulmonary and extrapulmonary
Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and
Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy.
Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly.
SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in
Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and
Onychomycosis of the fingernail due to dermatophytes (tinea unguium).
Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis.
(See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.)
Published Studies Related to Sporanox (Itraconazole)
Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. [2011.08]
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks...
Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. [2011.05]
Itraconazole is currently used for the treatment of cutaneous sporotrichosis. Terbinafine at a daily dose of 250 mg has been successfully applied to the treatment of cutaneous sporotrichosis. OBJECTIVE: To compare the efficacy of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis... CONCLUSION: Terbinafine administered at a daily dose of 250 mg is an effective and well-tolerated option for the treatment of cutaneous sporotrichosis.
Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. [2011.04]
OBJECTIVE: To investigate the pharmacokinetic interaction between ciprofloxacin and itraconazole in healthy male volunteers... CONCLUSION: Ciprofloxacin decreases the metabolism of itraconazole, most likely through inhibition of CYP3A4. The dosage of itraconazole should be reduced and its therapeutic outcome should be monitored closely when these two agents are concomitantly administered. Copyright (c) 2011 John Wiley & Sons, Ltd.
Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study. [2011.03]
PURPOSE: The risk of invasive fungal infection is greater for allogeneic hematopoietic stem cell transplantation (HSCT) than for autologous transplantation. Therefore, many transplantation centers use antifungal prophylaxis for allogeneic HSCT, however, there exists no standard guidelines or consensus regarding autologous HSCT... CONCLUSION: Although beneficial effects such as a shorter duration of fever and reduced need for antibiotic use were observed in the prophylaxis group, the results were not sufficient to draw a definite recommendation about the routine use of antifungal prophylaxis in pediatric autologous HSCT recipients with high-risk solid tumors (Trial registration: NCT00336531).
Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. [2011.03]
BACKGROUND: Primary observation of using itraconazole pulse regimen (commonly used for onychomycosis) in five sporotrichosis patients produced satisfactory effect, but there are no randomized controlled trials to assess this regimen and to compare with routine continuous regimen. OBJECTIVES: The aim of this study was to compare the efficacy and safety of itraconazole pulse regimen, as a new treatment option for cutaneous sporotrichosis, with continuous regimen... CONCLUSION: The efficacy and safety of Itraconazole pulse regimen for cutaneous sporotrichosis were similar to the continuous regimen. It is an effective and safe alternative treatment for cutaneous sporotrichosis, which can also lower the cost by decreasing the number of capsules. (c) 2010 The Authors. Journal of the European Academy of Dermatology and Venereology (c) 2010 European Academy of Dermatology and Venereology.
Clinical Trials Related to Sporanox (Itraconazole)
A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer [Recruiting]
To evaluate the 3-month event-free survival of the combination of the combination of
itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung
To determine the objective response rate of the combination of itraconazole and pemetrexed
in patients with recurrent/refractory non-small cell lung cancer.
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation [Recruiting]
- The primary objective of this study is to evaluate the efficacy and safety profile of
itraconazole as in primary prophylaxis
- The second objective of this study is to find the difference between long-term versus
short-term sequential therapy of Itraconazole (intravenous followed by oral
itraconazole) as primary prophylaxis of invasive fungal infections (IFI) in patients
undergoing allogeneic stem cell transplantation (allo-SCT)
- also to explore the relationship between the incidence of IFI with plasma
concentrations of itraconazole and hydroxy-itraconazole
Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. [Active, not recruiting]
Onychomycosis is a common condition accounting for approximately half of all nail disorders.
It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment
of onychomycosis in the United States with an approved dosage regimen for the treatment of
onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two
100mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200mg tablet which could
be used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will
compare the efficacy and safety of this new tablet formulation with itraconazole capsules and
A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy [Recruiting]
This research is being done to test an investigational drug, called itraconazole, in the
treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration
(FDA) for the treatment of various fungal infections such as fingernail/toenail infections
and other more serious fungal infections. The word "investigational" means that itraconazole
is not approved for use in people with cancer. However, the FDA is allowing the use of
itraconazole in this research study. Itraconazole has been shown to have activity against
cancer (including prostate cancer) in the laboratory, but has not been tested against cancer
The purpose of this study is to find out:
- If itraconazole is safe when given at two different doses
- How itraconazole affects prostate specific antigen (PSA): a blood test that measures
substances released by prostate cancer
- Whether itraconazole can delay further prostate cancer growth and spread
- How itraconazole affects other markers of prostate cancer
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas [Recruiting]
BCCs are the most common human cancer in the US and affect over 1 million people. There is
no effective drug to prevent basal cell carcinomas of the skin. We hope to learn if an oral
antifungal drug, Itraconazole, might inhibit a marker of proliferation and a biomarker
(tumor signaling pathway) of BCC development. Itraconazole is an FDA-approved drug for the
treatment of fungal infections of the skin, and has been used for the past 25 years with
relatively few side effects. It has been shown in mice to reduce a BCC biomarker and to
reduce growth of BCCs. Thus, it could potentially reduce BCC growth in humans.
Reports of Suspected Sporanox (Itraconazole) Side Effects
Oedema Peripheral (7),
Drug Ineffective (5),
Cardiac Failure Congestive (5),
Self Injurious Behaviour (5),
Diabetes Mellitus (4),
Erectile Dysfunction (4), more >>
Page last updated: 2011-12-09